Open Access

Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway

  • Authors:
    • Yong Zhang
    • Qiuyan Weng
    • Jinming Han
    • Jianming Chen
  • View Affiliations

  • Published online on: December 13, 2019     https://doi.org/10.3892/mmr.2019.10882
  • Pages: 675-684
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Osteosarcoma is the most common type of malignant bone cancer and results in cancer‑related deaths among adolescents. Alantolactone (ALT) demonstrates antitumor properties in various diseases; however, its potential role in osteosarcoma is relatively unclear. The aim of the present study was to evaluate the effect of ALT on osteosarcoma. ALT significantly decreased the viability of U2OS and HOS osteosarcoma cell lines. Cells flow cytometry assay and Hoechst 33258 staining assay revealed that ALT significantly increased the proportion of apoptotic U2OS cells. In addition, wound healing and Transwell invasion assays demonstrated that the invasion and migration of osteosarcoma were markedly reduced upon ALT treatment. It was hypothesized that the antitumor functions of ALT are mediated through inhibition of the PI3K/AKT signaling pathway. In conclusion, the results of the present study confirmed the inhibition of ALT on osteosarcoma cells via downregulation of PI3K/AKT signaling pathways, suggesting ALT as a potential therapeutic candidate for osteosarcoma.
View Figures
View References

Related Articles

Journal Cover

February 2020
Volume 21 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhang, Y., Weng, Q., Han, J., & Chen, J. (2020). Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway. Molecular Medicine Reports, 21, 675-684. https://doi.org/10.3892/mmr.2019.10882
MLA
Zhang, Y., Weng, Q., Han, J., Chen, J."Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway". Molecular Medicine Reports 21.2 (2020): 675-684.
Chicago
Zhang, Y., Weng, Q., Han, J., Chen, J."Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway". Molecular Medicine Reports 21, no. 2 (2020): 675-684. https://doi.org/10.3892/mmr.2019.10882